Desk note · industry · Packaged food / regulation
On 21 October 2026, the Food Safety and Standards Authority of India issued enforcement notices to Nestlé India, Zydus Wellness, Abbott Healthcare, and others over promotional claims on infant and children’s products, including Complan, Lactogen Pro 1, and NAN Excella Pro Stage 1, days after proposing a ban on added sugars in infant foods up to six months.
On 21 October 2026, India’s food safety regulator issued fresh enforcement notices to large packaged-food companies over how they market products aimed at infants and children. The Food Safety and Standards Authority of India named Nestlé India, Zydus Wellness, Abbott Healthcare, and other parties in actions tied to items such as Complan, Lactogen Pro 1 Powder, and NAN Excella Pro Stage 1 infant formula. Regulators asked Nestlé to back claims about digestive and immune benefits on its infant powders. Zydus was told to provide scientific justification for Complan slogans promising faster height growth. FSSAI also moved against social media promotion of infant milk substitutes, citing an Instagram reel and issuing notices to influencer Ira Fathima alongside corporate respondents. Abbott said it was not involved in the reel and does not endorse the claims shown. The wave lands days after FSSAI proposed banning added sucrose and fructose in foods for babies up to six months and as the authority pushes harder on front-of-pack warning labels across the packaged food industry.
When regulators question both pack copy and influencer posts, compliance is no longer a factory-floor checklist. Marketing teams must match what appears on the label, in the ad, on the e-commerce tile, and in a creator’s video. Infant formula and children’s nutrition sit in a tighter box because mis-stated health promises touch young consumers. Notices do not automatically pull products from shelves, but they signal that Delhi is willing to name global brands in public posts and demand evidence files. Nestlé’s response that September label issues were already answered shows companies will argue process, while FSSAI is building a paper trail ahead of possible penalties or reformulation orders. The pattern fits October’s wider sweep on infant sugars, warehouse raids, and misleading claims against other FMCG names.
If you buy Complan, lactogen-style formula, or toddler drinks, compare pack claims with the legal product category in the fine print before you stock up for the festive pantry run. Parents should treat influencer reels on infant foods as advertising subject to the same rules as television spots. Retailers and quick-commerce operators may see more delistings or label refreshes on apps while cases move. Investors in listed food companies should watch whether notices convert into fines, recalls, or simply legal fees. Track company responses in exchange filings, court challenges to FSSAI’s label push, and whether smaller brands face the same scrutiny as multinationals.
Telecom / IPO
On 22 October 2026, exchange data showed Jio Platforms’ ₹30,213 crore issue had drawn about ₹3.73 lakh crore of total bids by late evening on Day 2, with the retail portion oversubscribed and market commentators citing diverted cash from other listed stocks during the book build.
SEBI / market infrastructure
On 22 October 2026, the Securities and Exchange Board of India proposed letting stock exchanges and depositories fund core-market and regulator-mandated initiatives without prior approval for each ticket, while keeping board oversight and financial safeguards and inviting comments until 12 November.
E-commerce / food delivery
On 22 October 2026, reporting said Flipkart is testing an internal food delivery product called Eat-in by Minutes with more than 8,000 employees in Bengaluru, using Ekart logistics as it prepares to compete with Zomato and Swiggy in meal delivery.
Digital trust / compliance
On 22 October 2026, eMudhra Ltd said its board will voluntarily withdraw from the global SSL/TLS certificate segment after a key-security incident on eight intermediate certificates, citing compliance cost and weak economics while stressing that other digital-trust services continue.
For informational purposes only. Not investment advice. Verify with filings and a licensed adviser.